Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 811-821

  Krop, Ian E ^a   Mayer, Ingrid A ^b   Ganju, Vinod ^c   Dickler, Maura ^d   Johnston, Stephen ^e   Morales, Serafin ^f   Yardley, Denise A ^g   Melichar, Bohuslav ^h   Forero Torres, Andres ⁱ   Lee, Soo Chin ^j   de Boer, Richard ^k   Petrakova, Katarina ^l   Vallentin, Susanne ^m   Perez, Edith A ⁿ   Piccart, Martine ^o   Ellis, Matthew ^p   Winer, Eric ^a   Gendreau, Steven ^q   Derynck, Mika ^q   Lackner, Mark ^q   Levy, Gallia ^q   Qiu, Jiaheng ^q   He, Jing ^q   Schmid, Peter ^r   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c Peninsula Oncology Centre   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h PALACKÝ UNIVERSITY   (Czech Republic)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^m GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁿ MAYO CLINIC   (United States)

^o JULES BORDET INSTITUTE   (Belgium)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q GENENTECH INC   (United States)

^r QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PLACEBO; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONIST; TUMOR MARKER;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER FATIGUE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLITIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INTENTION TO TREAT ANALYSIS; MACULOPAPULAR RASH; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PIK3CA GENE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FOLLOW UP; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84964950086     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00106-6     Document Type: Article

References (30)

1. 1 Ring, A, Dowsett, M, Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11 (2004), 643–658.
2. 2 Johnston, SR, New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16 (2010), 1979–1987.
3. 3 Miller, TW, Hennessy, BT, González-Angulo, AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120 (2010), 2406–2413.
4. 4 Shou, J, Massarweh, S, Osborne, CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 (2004), 926–935.
5. 5 Baselga, J, Semiglazov, V, van Dam, P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27 (2009), 2630–2637.
6. 6 Bachelot, T, Bourgier, C, Cropet, C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30 (2012), 2718–2724.
7. 7 Baselga, J, Campone, M, Piccart, M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366 (2012), 520–529.
8. 8 Piccart, M, Hortobagyi, GN, Campone, M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25 (2014), 2357–2362.
9. 9 Maruyama, N, Miyoshi, Y, Taguchi, T, Tamaki, Y, Monden, M, Noguchi, S, Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13 (2007), 408–414.
10. 10 Kalinsky, K, Jacks, LM, Heguy, A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15 (2009), 5049–5059.
11. 11 Miller, TW, Pérez-Torres, M, Narasanna, A, et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69 (2009), 4192–4201.
12. 12 Abramson, VG, Cooper Lloyd, M, Ballinger, T, et al. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res Treat 145 (2014), 389–399.
13. 13 Loi, S, Haibe-Kains, B, Majjaj, S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 107 (2010), 10208–10213.
14. 14 Loi, S, Michiels, S, Baselga, J, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One, 8, 2013, e53292.
15. 15 Sabine, VS, Crozier, C, Brookes, CL, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32 (2014), 2952–2958.
16. 16 Hortobagyi, GN, Piccart-Gebhart, MJ, Rugo, HS, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol, 31(suppl), 2013 abstract LBA509.
17. 17 Fu, X, Creighton, C, Biswal, NC, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res, 16, 2014, 430.
18. 18 O'Brien, C, Wallin, JJ, Sampath, D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16 (2010), 3670–3683.
19. 19 Sarker, D, Ang, JE, Baird, R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21 (2015), 77–86.
20. 20 von Hoff, DD, LoRusso, P, Demetri, GD, et al. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol, 29(suppl), 2011 abstract 3052.
21. 21 Robertson, JF, Osborne, CK, Howell, A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 (2003), 229–238.
22. 22 Mayer, IA, Abramson, VG, Balko, JM, et al. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). J Clin Oncol, 30(suppl), 2012 abstract 510.
23. 23 Schmid, P, Pinder, SE, Wheatley, D, et al. Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study). Cancer Res, 75, 2015 abstract S2-03.
24. 24 Slamon, DJ, Hurvitz, SA, Chen, D, et al. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: combined exploratory analysis from BOLERO-1 and BOLERO-3. J Clin Oncol, 33(suppl), 2015 abstract 512.
25. 25 Robinson, DR, Wu, YM, Vats, P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45 (2013), 1446–1451.
26. 26 Ross-Innes, CS, Stark, R, Teschendorff, AE, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481 (2012), 389–393.
27. 27 Juric, D, Argiles, G, Burris, HA, et al. Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC). Cancer Res, 72, 2012 abstract P6-10-07.
28. 28 Olivero, AG, Heffron, TP, Baumgardner, M, et al. Discovery of GDC-0032: a beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Res, 73, 2013 abstract DDT02-01.
29. 29 Saura, C, Sachdev, J, Patel, MR, et al. Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer. Cancer Res, 75, 2015 abstract PD5-2.
30. 30 Juric, D, Krop, I, Ramanathan, RK, et al. GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase Ia dose escalation study. Cancer Res, 73, 2013 abstract LB-64.